CAMBRIDGE, Mass.–(BUSINESS WIRE)–Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Holdings Corp. (https://samyangbiopharm.com/eng), announced today that Eun-Ju Ryu has been appointed President of Samyang Biopharm USA, end of Jan. 2022.
“Eun-Ju’s proven leadership capabilities are exceptional and I am confident that she is the right leader for Samyang Biopharm USA as the company continues its transition into a fully-integrated, global company delivering on the promise of an emerging pipeline,” said Dr. Young Joon Lee, Head of Biopharm Group,, Samyang Holdings Corp. “During her impressive career, she has led key elements of business development, commercial and R&D in select therapeutic areas including oncology and rare disease. This experience will help Samyang Biopharm USA reach the next level of growth and achievement.”
Ms. Ryu brings over 30 years of experience in the biopharmaceutical industry to her leadership position at Samyang Biopharm USA. Prior to this appointment she held a series of escalating management positions in various companies, including 12 years at Pfizer Inc. (USA) and 6 years at Pfizer Korea. Her career started as a Regulatory manager, then expanded roles in Clinical Trial Management team, Business Development and Global marketing. After she served as a Head of Oncology and Specialty Business Unit at Pfizer Korea, she moved to New York headquarter as a Japan Asia regional commercial lead in 2006. Once moved to the US, she was leading Global Marketing and Portfolio Maximization and Acquisition in various therapeutic areas including Oncology, Rare Disease, Anti-Infectives, and Neuroscience. She was awarded by the Minister of Health and Welfare for her contribution in US-Korea collaboration. Her continuous community service has been recognized by the County Community leadership award. She also worked as a CEO of Korean Community Center and a Chief Business Development Officer in Diagnostic Company. Eun Ju Ryu received her Bachelor’s degree in Pharmacy at Ewha Womans University, Master’s in Clinical Pharmacy at Sookmyung Women’s University, and MBA degree at New York University in the US. Eun-Ju joins as President of Samyang Biopharm USA in end of Jan. 2022.
“I am excited to become President of Samyang Biopharm USA as the company continues to build its pipeline in select oncology indications with the ultimate goal of providing life-changing medicines for patients,” said Ms. Eun-Ju Ryu, President of Samyang Biopharm USA. “It is an honor to lead this team of committed scientists and business leaders who are dedicated to changing the lives of patients and making our vision a reality. As the company builds upon its initial success and expands its portfolio with promising new research programs, I believe we are in a position to drive substantial growth over the long term.”
About Samyang Biopharm USA, Inc.
Samyang Biopharm USA, a global biopharmaceutical company focused on the global development of first-in class biologic therapeutics for oncology and rare disease indications, was established as a subsidiary of Samyang Biopharmaceuticals Corporation (South Korea) in August 2018 and in 2021 became a subsidiary of Samyang Holdings Corp. Through collaborations, partnerships and in-licensing, Samyang Biopharm USA seeks to identify promising pre-clinical and early clinical candidates and advance them through clinical development with the objective of improving the lives of patients worldwide. The company’s current pipeline includes the anti-MIC immuno-oncology asset SYB-010 currently in IND enabling studies.
